Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study

Who May Qualify: - Patients aged 15-75 years with Fabry disease confirmed by enzyme assay and gene test - Patients have not undergone ERT for more than 12 months or patients have not used Agalsidase Alfa in the last 12 months. - Patients who have cardiac involvement of Fabry disease (end diastolic maximal wall thickness ≥ 12mm on echocardiography or CMR, decreased native T1 value on CMR, unexplained distinct diastolic dysfunction, unexplained decreased global longitudinal strain on 2D strain echocardiography, or biopsy-proven cardiac involvement) - Patients provided written willing to sign a consent form to participate in this study - The patient, or patient's legally authorized representative(s), if applicable, understands the nature, scope, and possible consequences of the study and has provided written willing to sign a consent form that has been approved by the Institutional Review Board/Independent Ethics Committee - The patient must be sufficiently cooperative to participate in this clinical study as judged by the investigator. Who Should NOT Join This Trial: - Contraindication for enzyme replacement treatment with Agalsidase Alfa - Patients have previously been treated with Agalsidase Alfa for \> 12 months - Patients unable to undergo PET-CMR due to any condition - Patients who are pregnant - Patients who have active malignancy - Subject who the investigator deems inappropriate to participate in this study Always talk to your doctor about whether this trial is right for you.